FGFR

The fibroblast growth factor receptors (FGFR) are, as their name implies, receptors that bind to members of the fibroblast growth factor (FGF) family of proteins. Some of these receptors are involved in pathological conditions. For example, a point mutation in FGFR3 can lead to achondroplasia.

Cat. No.	Product name	CAS No.	Purity
T8525	EGFR-IN-16	133550-22-8	98%
T8525	EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.
T3492	PD-166866	192705-79-6	99.98%
T3492	PD-166866 is a selective FGFR tyrosine kinase inhibitor.
T5001	Nintedanib esylate	656247-18-6	99.96%
T5001	Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
TQ0228	Derazantinib	1234356-69-4	99.95%
TQ0228	Derazantinib (ARQ-087) (ARQ-087) is an ATP competitive tyrosine kinase inhibitor. It exhibits potent activity against FGFR1/FGFR2/FGFR3 chondrocytes (IC50s: 4.5 ...
T2857	2,5-Dihydroxybenzoic acid	490-79-9	99.92%
T2857	2,5-Dihydroxybenzoic acid (Gentisic acid) is an active metabolite of salicylic acid degradation with a broad spectrum of biological activity, such as anti-inflam...
T2609	Masitinib	790299-79-5	99.91%
T2609	Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 200...
T2341	KW-2449	1000669-72-6	99.89%
T2341	KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R...
T6124	Mubritinib	366017-09-6	99.87%
T6124	Mubritinib (TAK-165) (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM.
T5473	ASP5878	1453208-66-6	99.86%
T5473	ASP5878 potently inhibited the tyrosine kinase activities of recombinant FGFR1, 2, 3, and 4 with IC50 values of 0.47, 0.60, 0.74, and 3.5 nmol/L.
T2638	Gandotinib	1229236-86-5	99.86%
T2638	LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM). The selectivity is higher 8- and 20-fold than JA...
T7738	H3B-6527	1702259-66-2	99.85%
T7738	H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma, with antineoplastic activity.
T2347	BLU9931	1538604-68-0	99.85%
T2347	BLU9931 is the first selective small molecule inhibitor of FGFR4.
T1777	Nintedanib	656247-17-5	99.85%
T1777	Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108...
T0097L	Pazopanib	444731-52-6	99.84%
T0097L	Pazopanib (GW786034), a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibi...
T16486	Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD	1037589-69-7	99.83%
T16486	Mal-amido-PEG2-C2-amido-Ph-C2-CO-AZD (PF-05231023) is a long-acting fibroblast growth factor 21 (FGF21) analog and is an FGF21-receptor agonist. It is also suita...
T8492	BO-264	2408648-20-2	99.81%
T8492	BO-264 is a highly potent and orally active inhibitor of transforming acidic coiled-coil 3 (TACC3, IC50 of 188 nM and a Kd of 1.5 nM).
T0520	Lenvatinib	417716-92-8	99.8000%
T0520	Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib h...
T6289	Dovitinib	405169-16-6	99.78%
T6289	Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) an...
T2372	Ponatinib	943319-70-8	99.74%
T2372	Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively)...
T2446	KI8751	228559-41-9	99.73%
T2446	KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.